

Andrew A Wagner

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4495034/andrew-a-wagner-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

127
papers

3,588
citations

32
h-index

57
g-index

147
ext. papers

4,707
ext. citations

5.1
avg. IF

5.02
L-index

#	Paper	IF	Citations
127	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101829	2.2	1
126	The effect of day of discharge on hospital readmission after minimally invasive partial nephrectomy.. <i>Canadian Journal of Urology</i> , 2022 , 29, 11080-11086	0.8	
125	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results From the Canary PASS Cohort. <i>Journal of Urology</i> , 2021 , 101097JU0000000000002354	2.5	
124	Intracorporeal Versus Extracorporeal Neobladder After Robot-assisted Radical Cystectomy: Results From the International Robotic Cystectomy Consortium. <i>Urology</i> , 2021 ,	1.6	2
123	-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3660-3670	2.2	10
122	Radical prostatectomy versus external beam radiation therapy for high-grade, clinically localized prostate cancer: Emulation of a target clinical trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 785.e1-785.e10	2.8	1
121	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021 , 127, 2934-2942	6.4	11
120	Reply by Authors. <i>Journal of Urology</i> , 2021 , 205, 1293	2.5	
119	Outcomes of Active Surveillance for Young Patients with Small Renal Masses: Prospective Data from the DISSRM Registry. <i>Journal of Urology</i> , 2021 , 205, 1286-1293	2.5	12
118	Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 927-935	3.8	
117	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2021 , 92, 493-499	4.3	1
116	Upstaging and Survival Outcomes for Non-Muscle Invasive Bladder Cancer After Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>Journal of Endourology</i> , 2021 , 35, 1541-1547	2.7	0
115	Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials. <i>Journal of Urology</i> , 2021 , 205, 1689-1697	2.5	7
114	Misaligned Incentives in Benign Prostatic Enlargement Surgery: More Complex and Efficacious Procedures Are Earning Fewer Relative Value Units. <i>Journal of Endourology</i> , 2021 , 35, 835-839	2.7	1
113	Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. <i>Oncologist</i> , 2021 , 26, e863-e873	5.7	8
112	Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. <i>Cancer</i> , 2021 , 127, 884-893	6.4	8
111	Reducing postoperative opioid pill prescribing via a quality improvement approach. <i>International Journal for Quality in Health Care</i> , 2021 , 33,	1.9	2

110	Rates and Patterns of Recurrences and Survival Outcomes after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>Journal of Urology</i> , 2021 , 205, 407-413	2.5	7
109	Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 3861-3866	12.9	2
108	Contemporary Incidence and Predictors of Occult Inguinal Lymph Node Metastases in Men With Clinically Node-negative (cN0) Penile Cancer. <i>Urology</i> , 2021 , 153, 221-227	1.6	2
107	Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. <i>Journal of Urology</i> , 2021 , 206, 80-87	2.5	11
106	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. <i>Future Oncology</i> , 2021 , 17, 2923-2939	3.6	5
105	Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 1422-1432	4.5	1
104	Perioperative Aspirin Use is Associated with Bleeding Complications during Robotic Partial Nephrectomy. <i>Journal of Urology</i> , 2021 , 101097JU0000000000002240	2.5	0
103	Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 1343-1350	13.4	5
102	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. <i>Cancer</i> , 2021 ,	6.4	1
101	Using Preoperative Pelvic Floor Assessment to Predict Early Return of Continence after Robotic Radical Prostatectomy. <i>Urology</i> , 2021 , 155, 160-164	1.6	
100	Portuguese version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): psychometric validation and prospective application for early functional outcomes at a single institution. <i>BMC Urology</i> , 2020 , 20, 163	2.2	3
99	Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1693-1701	2.2	40
98	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1549-1557	2.2	26
97	Patient-Reported Quality of Life and Convalescence After Minimally Invasive Kidney Cancer Surgery. <i>Urology</i> , 2020 , 144, 123-129	1.6	2
96	Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1266-1276	27.4	91
95	Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5503-5503 ²	2.2	7
94	Reply by Authors. <i>Journal of Urology</i> , 2020 , 203, 733	2.5	
93	Neoadjuvant Chemotherapy is Not Associated with Adverse Perioperative Outcomes after Robot-Assisted Radical Cystectomy: A Case for Increased Use from the IRCC. <i>Journal of Urology</i> , 2020 , 203, 57-61	2.5	11

92	African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. <i>Journal of Urology</i> , 2020 , 203, 727-733 ²⁵	20
91	Nonlinear microscopy for detection of prostate cancer: analysis of sensitivity and specificity in radical prostatectomies. <i>Modern Pathology</i> , 2020 , 33, 916-923	9.8 7
90	The incidence, predictors, and survival of disappearing small renal masses on active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 42.e1-42.e6	2.8 1
89	A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. <i>European Journal of Cancer</i> , 2020 , 126, 21-32 ^{7.5}	8
88	Comparison of the Comprehensive Complication Index and Clavien-Dindo systems in predicting perioperative outcomes following radical nephroureterectomy. <i>Translational Andrology and Urology</i> , 2020 , 9, 1780-1785	2.3 2
87	Incidence and preoperative predictors for major complications following radical nephroureterectomy. <i>Translational Andrology and Urology</i> , 2020 , 9, 1786-1793	2.3 1
86	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. <i>JAMA Oncology</i> , 2020 , 6, e203187	13.4 14
85	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020 , 126, 98-104 ^{6.4}	14
84	Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. <i>Investigational New Drugs</i> , 2020 , 38, 831-843	4.3 32
83	A comparative propensity score-matched analysis of perioperative outcomes of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. <i>BJU International</i> , 2020 , 126, 265-272	5.6 37
82	Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 7287-7293 ^{13.9}	25
81	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 438-445 ^{6.2}	12
80	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 478-487	40 148
79	Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma. <i>Clinical Cancer Research</i> , 2019 , 25, 5135-5142	12.9 11
78	Comparing histologic evaluation of prostate tissue using nonlinear microscopy and paraffin H&E: a pilot study. <i>Modern Pathology</i> , 2019 , 32, 1158-1167	9.8 19
77	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. <i>Journal of Clinical Oncology</i> , 2019 , 37, 923-931 ^{2.2}	42
76	Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer. <i>Urology</i> , 2019 , 127, 53-60	1.6 4
75	Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study. <i>BJU International</i> , 2019 , 123, 42-50	5.6 33

74	Reducing Pseudoaneurysm and Urine Leak After Robotic Partial Nephrectomy: Results Using the Early Unclamping Technique. <i>Urology</i> , 2019 , 132, 130-135	1.6	6
73	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. <i>Scientific Reports</i> , 2019 , 9, 14551	4.9	16
72	Performance of the 17-gene genomic prostate score test in men with prostate cancer (PCa) managed with active surveillance (AS): Results from the Canary Prostate Active Surveillance Study (PASS).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 262-262	2.2	
71	Continued 5 α -Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. <i>Journal of Urology</i> , 2019 , 201, 106-111	2.5	3
70	Selecting Patients with Small Renal Masses for Active Surveillance: A Domain Based Score from a Prospective Cohort Study. <i>Journal of Urology</i> , 2019 , 201, 886-892	2.5	9
69	Characteristics of mismatch repair deficiency in sarcomas. <i>Modern Pathology</i> , 2019 , 32, 977-987	9.8	25
68	Perceptions of Oncologists About Sharing Clinic Notes with Patients. <i>Oncologist</i> , 2019 , 24, e46-e48	5.7	1
67	Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2019 , 60, 605	2.9	10
66	Use of delayed intervention for small renal masses initially managed with active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 18-25	2.8	18
65	Delayed Return of Ejaculatory Function in Adolescent Males Treated With Retroperitoneal Lymph Node Dissection and Adjuvant Therapy for Paratesticular Rhabdomyosarcoma. <i>Urology</i> , 2019 , 124, 254-256	1.6	3
64	Collaborating with our adult colleagues: A case series of robotic surgery for suspicious and cancerous lesions in children and young adults performed in a free-standing children's hospital. <i>Journal of Pediatric Urology</i> , 2018 , 14, 182.e1-182.e8	1.5	12
63	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. <i>JAMA Oncology</i> , 2018 , 4, e180219	13.4	46
62	Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2018 , 73, 706-712	10.2	11
61	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. <i>European Urology</i> , 2018 , 74, 211-217	10.2	22
60	Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 364-372	6.2	29
59	An Unusual Presentation of Metastatic Urothelial Bladder Carcinoma With Rhabdoid Features Presenting as Obstructive Uropathy. <i>Urology</i> , 2018 , 115, 33-35	1.6	
58	Low Levels of Evidence for Neoadjuvant Chemotherapy to Treat Soft-Tissue Sarcoma. <i>JAMA Oncology</i> , 2018 , 4, 1169-1170	13.4	5
57	Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11502-11502	2.2	14

56	Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 79-79	2.2	2
55	Trends in Sales Volumes of Cancer Medicines in Six Asian Countries Working Toward Universal Health Coverage 2018 , 4, 220s-220s		1
54	When can active surveillance be less active? Prediction of long-term nonreclassification for men with low-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 140-140	2.2	
53	Immunohistochemical evaluation of p53, Ki67, ERG, MYC and PTEN in Gleason pattern 3 prostate cancer: Implication in active surveillance.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e17068-e17068	2.2	1
52	Pelvic Lymphadenectomy 2018 , 1048-1059		
51	Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy. <i>BMC Cancer</i> , 2018 , 18, 1296	4.8	11
50	The potential of emerging new therapeutics for the treatment of perivascular epithelioid cell tumors (PEComa). <i>Expert Opinion on Orphan Drugs</i> , 2018 , 6, 537-543	1.1	3
49	Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP. <i>Practical Radiation Oncology</i> , 2018 , 8, 445-451	2.8	1
48	YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. <i>Gynecologic Oncology</i> , 2017 , 145, 531-535	4.9	22
47	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. <i>Cancer</i> , 2017 , 123, 3285-3290	6.4	106
46	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2017 , 72, 448-454	10.2	49
45	Development of a patient and institutional-based model for estimation of operative times for robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. <i>BJU International</i> , 2017 , 120, 695-701	5.6	12
44	A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. <i>European Journal of Cancer</i> , 2017 , 76, 144-151	7.5	60
43	Early Oncologic Failure after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>Journal of Urology</i> , 2017 , 197, 1427-1436	2.5	32
42	Clinical Use of Expanded Prostate Cancer Index Composite for Clinical Practice to Assess Patient Reported Prostate Cancer Quality of Life Following Robot-Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2017 , 197, 109-114	2.5	18
41	The use of five-alpha reductase inhibitors and their association with reclassification and pathologic outcomes in the Canary Prostate Active Surveillance Study (PASS).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 22-22	2.2	
40	Tumor volume score (TVS), modified recist, and tissue damage score (TDS) as novel methods for assessing response in tenosynovial giant cell tumors (TGCT) treated with pexidartinib: Relationship with patient-reported outcomes (PROs).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11048-11048	2.2	0
39	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. <i>Journal of Urology</i> , 2016 , 195, 313-20	2.5	93

38	TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma. <i>Nature Communications</i> , 2016 , 7, 12609	17.4	53
37	Minimally invasive cytoreductive nephrectomy: a multi-institutional experience. <i>World Journal of Urology</i> , 2016 , 34, 1651-1656	4	17
36	Robotic Surgery of the Kidney, Bladder, and Prostate. <i>Surgical Clinics of North America</i> , 2016 , 96, 615-364	4	23
35	Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016 , 22, 2874-84	12.9	75
34	Active Surveillance for Small Renal Masses: A Review of the Aims and Preliminary Results of the DISSRM Registry. <i>Current Urology Reports</i> , 2016 , 17, 4	2.9	5
33	Gleason Misclassification Rate Is Independent of Number of Biopsy Cores in Systematic Biopsy. <i>Urology</i> , 2016 , 91, 143-9	1.6	17
32	Effect of Stereotactic Body Radiotherapy on the Growth Kinetics and Enhancement Pattern of Primary Renal Tumors. <i>American Journal of Roentgenology</i> , 2016 , 206, 544-53	5.4	23
31	Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. <i>Oncotarget</i> , 2016 , 7, 16581-92	3.3	44
30	Patient-reported Symptoms of Tenosynovial Giant Cell Tumors. <i>Clinical Therapeutics</i> , 2016 , 38, 778-93	3.5	45
29	A Prospective, Comparative Study of Quality of Life among Patients with Small Renal Masses Choosing Active Surveillance and Primary Intervention. <i>Journal of Urology</i> , 2016 , 196, 1356-1362	2.5	40
28	Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2016 , 61, 94-101	7.5	19
27	Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. <i>New England Journal of Medicine</i> , 2015 , 373, 428-37	59.2	309
26	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. <i>European Urology</i> , 2015 , 68, 1083-8	10.2	39
25	The natural history of renal functional decline in patients undergoing surveillance in the DISSRM registry. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 166.e17-20	2.8	8
24	Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. <i>Clinical Cancer Research</i> , 2015 , 21, 3178-86	12.9	23
23	Active Surveillance is Superior to Radical Nephrectomy and Equivalent to Partial Nephrectomy for Preserving Renal Function in Patients with Small Renal Masses: Results from the DISSRM Registry. <i>Journal of Urology</i> , 2015 , 194, 903-9	2.5	24
22	Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors. <i>Oral Oncology</i> , 2015 , 51, 1026-1033	4.4	30
21	A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2015 , 21, 1044-51	12.9	54

20	Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. <i>European Urology</i> , 2015 , 68, 408-15	10.2	190
19	CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1346-53	6.1	39
18	Real-world use of epic for clinical practice (EPIC-CP) to assess patient-reported prostate cancer quality of life in the clinical setting.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 18-18	2.2	1
17	Societal costs after renal cancer surgery.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 512-512	2.2	
16	Imaging features of primary and metastatic malignant perivascular epithelioid cell tumors. <i>American Journal of Roentgenology</i> , 2014 , 202, 252-8	5.4	49
15	Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2184-93	6.1	84
14	Sterotactic body radiosurgery for primary small renal tumors: A retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 475-475	2.2	1
13	International Robotic Radical Cystectomy Consortium: A way forward. <i>Indian Journal of Urology</i> , 2014 , 30, 314-7	0.8	6
12	Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 40-40	2.2	
11	Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. <i>Modern Pathology</i> , 2013 , 26, 289-94	9.8	119
10	A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. <i>Clinical Cancer Research</i> , 2013 , 19, 6020-9	12.9	62
9	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. <i>Cancer</i> , 2012 , 118, 1649-55	6.4	171
8	Targeted therapy in sarcoma: should we be lumpers or splitters?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 652-7	7.1	2
7	Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. <i>Cancer</i> , 2012 , 118, 5894-902	6.4	114
6	Cost comparison of robotic, laparoscopic, and open partial nephrectomy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 394-394	2.2	
5	Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. <i>Clinical Cancer Research</i> , 2011 , 17, 871-9	12.9	140
4	Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. <i>Cancer Research</i> , 2010 , 70, 639-45	10.1	80
3	Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. <i>Journal of Clinical Oncology</i> , 2010 , 28, 835-40	2.2	297

- | | | | |
|---|--|----|---|
| 2 | Specific targets in sarcoma and developmental therapeutics. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8, 677-85; quiz 686 | 73 | 3 |
| 1 | Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, 401-10 | 73 | 6 |